This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bruker Corporation Reports Fourth Quarter And Full Year 2012 Financial Results

On a non-GAAP basis, Bruker reported full year 2012 operating income of $219.0 million, or 12.2% of revenues, compared to $196.8 million, or 11.9% of revenues, in 2011. Non-GAAP 2012 EPS were $0.83, compared to $0.82 for the year 2011.

“Despite the challenges posed by weaker European economies, softness in U.S. academic markets, and the slowing of several industrial and applied market segments, Bruker’s innovation engine generated excellent top-line growth throughout 2012,” commented Frank Laukien, President and CEO of Bruker. “This performance is a testament to the strength of our customer relationships and our focus on addressing their needs. We are also pleased with our improving margins in the second half of 2012, and we recognize that we need to translate more of our healthy revenue growth into higher profits and cash flow.”

2012 Business Highlights

  • Launched over 30 new products, including several breakthrough innovations.
  • Increased 2012 non-GAAP operating margin by 30 basis points to 12.2%, compared to 11.9% in 2011.
  • Acquired SkyScan microCT business and Carestream’s preclinical in vivo imaging portfolio to provide Bruker with the broadest preclinical imaging product line in the industry.
  • Continued the rapid growth of MALDI Biotyper platform for clinical and non-clinical microbiology.
  • Organized 10 operating divisions of the Bruker Scientific Instruments (BSI) segment into three Groups.
  • Strengthened executive leadership with appointments of a new CFO and two new Group Presidents.
  • Strengthened operational leadership and initiated new outsourcing programs and other productivity improvement efforts.

“As Bruker enters 2013, we are analyzing and implementing various initiatives to drive increased profitability and cash flow. In addition to ongoing improvements in operational processes and systems, we are taking targeted actions to optimize the cost structure of certain businesses,” said Charles Wagner, Chief Financial Officer of Bruker. “For the full year 2013, the Company expects year-over-year reported revenue growth of 4 to 5 percent and non-GAAP EPS growth of 6 to 10 percent.”

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,802.81 -125.39 -0.70%
S&P 500 2,073.30 -16.16 -0.77%
NASDAQ 4,901.9070 -37.42 -0.76%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs